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Abstract
The hypothesis that cancer stem cells are responsible for the
chemoresistant and metastatic phenotypes of many breast cancers
has gained support using cell-sorting strategies to enrich the
tumor-initiating population of cells. The mechanisms regulating the
cancer stem cell pool, however, are less clear. Two recent publi-
cations suggest that loss of p53 permits expansion of presumptive
cancer stem cells in mouse mammary tumors and in human breast
cell lines. These results add restriction of cancer stem cells as a
new tumor suppressor activity attributed to p53.
Enrichment of tumor-initiating cells in
p53-deficient mammary tumor models
The recent identification and characterization of stem cells in
a variety of adult tissues has led to renewed interest in the
role of stem cells in cancers. Cancer stem cells are hypothe-
sized to be a small population of cells within a tumor that are
capable of self-renewal and that can undergo differentiation
to generate the phenotypic heterogeneity observed in tumors.
Contemporary methods for studying cancer stem cells have
most often used cell surface markers to enrich the subset of
cells capable of initiating a tumor upon transplantation into an
appropriate host. Molecular pathways that limit expansion of
the tumor-initiating cell population could be targeted to
eradicate tumors.
Using mammary tumors arising spontaneously from trans-
plants of BALB/c-Trp53–/– mammary epithelium, Zhang and
coworkers show that cells expressing markers of mouse
mammary stem cells (lin–/CD29hi/CD24hi) had a greater
tumor-initiating frequency [1]. This observation was
consistent among tumors with heterogeneous expression of
markers for the luminal epithelium and the basal epithelium.
The lin–/CD29hi/CD24hi population shared additional features
of mammary stem cells, including radiation resistance and the
formation of secondary mammospheres.
But how might loss of p53 lead to formation or expansion of
the tumor-initiating pool? Using a unique culture model of
luminal breast epithelial cells (BPEC-T), Godar and co-
workers demonstrate that p53 binds to the promoter of
CD44 [2], a commonly used marker of cancer stem cells [3],
and represses CD44 expression. Constitutive expression of
CD44 blocked p53-dependent apoptosis and rendered cells
resistant to doxorubicin. Conversely, suppression of CD44
expression restricted tumor-initiating cells.
These results link the loss of p53 function to increased
expression of CD44, which promotes expansion of tumor-
initiating cells purified in tumors. The p53 protein appears to
play a similar role in embryonic stem cells, where p53
represses expression of Nanog – which limits the pool of
pluripotent cells [4,5]. In contrast, loss of p53 extends the
repopulating activity of tissue-specific stem cells [6,7].
Disruption of BRCA1 also allows expansion of breast stem
cells [8]. The restriction of stem cells may therefore be a
fundamental pathway for tumor suppression.
Reading between the cell lines
While expansion of the tumor-initiating cell population in p53-
deficient mammary epithelial cells is consistent in both mouse
mammary and human breast epithelial cells, the role of CD44
is not. Although loss of p53 expression resulted in increased
levels of CD44 protein in BPEC-T cells and in basal
mammary epithelium of Trp53–/– mice [2], there was no
enrichment for tumor-initiating cells within the CD44+/CD24–
population in BALB/c-Trp53–/– mammary tumors [1]. This
apparent discrepancy points to heterogeneity in the expres-
sion of markers among cancer stem cells. In mammary tumors
from Brca1ΔExon11/Trp53+/– mice, two discrete tumor-initiating
populations were identified that express either CD44+/CD24–
or CD133+ [9]. As coexpression of CD44 and CD133 was
not detected in these pools of cells, it appears that CD44 is
not essential for sustaining the pool of cancer stem cells.
Indeed, p53 represses expression of more than 20 target
genes [10] that may contribute to maintenance of the pool of
tumor-initiating cells. Genes such as Nanog may have direct
actions in supporting self-renewal of cancer stem cells,
allowing the pool to expand. Loss of p53 would also allow
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increased expression of the multidrug-resistance gene
(ABCB1 or  MDR1) that renders cells resistant to chemo-
therapies. Similarly, both increased proliferation and
decreased apoptosis would be expected to result from de-
repression of CDC25C and BIRC5/Survivin when p53
function is disrupted. CD44 may therefore be only one
mechanism by which p53 may act to restrict the tumor-
initiating population of cancer cells.
Cancer stem cells: puppet or puppeteer?
It is clear that that p53 plays a pivotal role in tumor
suppression. Mutation and loss of function of p53 are among
the most common alterations in epithelial cancers [11], and
gene expression signatures associated with dysfunctional
p53 have been shown to predict patient survival [12,13]. The
p53 protein regulates a variety of pathways (cell cycle arrest,
apoptosis, DNA repair, senescence and autophagy) that can
contribute to suppression of tumors. The publications by
Zhang and colleagues and by Godar and colleagues now
add suppression of cancer stem cells as an additional activity
by which p53 can inhibit tumors [1,2]. So which of these
pathways dominate? The answer will have significant impact
on therapeutic strategies.
On the one hand, loss of p53 may promote genetic instability –
resulting in plasticity of phenotypes due to random mutations
and clonal evolution (Figure 1). In this model, the behavior of
the p53-deficient cancer cells would be stochastic and would
require therapeutics targeting multiple oncogenic pathways. If
the apparent phenotypic plasticity of p53-deficient breast
tumors is due to the expansion of the cancer stem cell pool,
however, therapies targeting the self-renewal pathways may
be extremely effective. Loss of p53 function in breast tumors
is strongly correlated with the basal-like gene expression
signatures [14,15]. This suggest that either these tumors
originate from breast stem cells or that loss of p53 allows
cancer cells to acquire characteristics of stem cells. These
results favor the possibility that p53 deficiency allows expan-
sion of cancer stem cells and that the expression profiles of
tumor-initiating cells will identify effective therapeutic targets.
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